Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

real-time data

Novartis building

Pharma waits for Glivec patent verdict in India

Intellectual property decision could have far-reaching consequences for industry

- PMLiVE

Boehringer – Lilly file empagliflozin for European approval

EMA begins review of the companies' new type 2 diabetes drug

Biogen Idec building

Biogen Idec’s Tecfidera approved in US

Green light from FDA closely follows MS drug's European approval

- PMLiVE

Interview: Pierre Chancel, Sanofi Diabetes

The head of Sanofi Diabetes shares the company’s strategy to keep pace with the race against this ‘hidden disease’

- PMLiVE

Eisai expands into Russia with Halaven launch

Breast cancer drug will be followed by epilepsy portfolio

David Novack leaves Novartis for Dynavax

Was global head of technical operations and supply chain for diagnostics at Swiss pharma firm

- PMLiVE

Star Commercial Academy appoints Gary Lunt

He joins having recently held senior positions within Celesio

- PMLiVE

EMA launches diabetes drugs safety review

Will investigate pancreatitis risks in two major drug classes

- PMLiVE

NICE gives final ‘yes’ to cystic fibrosis drugs from Novartis and Forest

NICE backs Tobi Podhaler and Colobreathe for NHS use

- PMLiVE

Otsuka files new TB candidate in Japan as shortages worsen

Delamanid shows promise in multi-drug resistant TB but supplies of rifampin are low

- PMLiVE

Otsuka licenses Lundbeck’s Alzheimer’s drug in $825m deal

Lu AE58054 is in phase III development as add-on to donepezil

- PMLiVE

NICE: Pfizer’s lung cancer drug Xalkori too expensive for NHS

Pharma company says NICE's data demands need to take ethics into account

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links